ASTRAZENECA PRESENTS POSITIVE TAGRISSO (OSIMERTINIB) FOLLOW-UP DATA IN LUNG CANCER AT ELCC 2016
Phase I first-line Tagrisso (osimertinib) data show an objective response rate of 77%, and progression-free survival of 19.3 months in patients with EGFRm NSCLC1 Updated results in pre-treated patients with EGFR T790M mutation-positive NSCLC further support recent approvals in the US, EU and Japan